{"name":"Kolon Life Science","slug":"kolon-life-science","ticker":"","exchange":"","domain":"","description":"Kolon Life Science is a biotechnology company focused on developing innovative treatments for various diseases, with a strong emphasis on regenerative medicine and gene therapy. The company has a diverse pipeline of five drugs in different stages of clinical development, including Invossa K Inj., which is in Phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Invossa K Inj.","genericName":"Invossa K Inj.","slug":"invossa-k-inj","indication":"Osteoarthritis of the knee (Phase 3)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"KLS-2031","genericName":"KLS-2031","slug":"kls-2031","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Invossa K Inj.","genericName":"Invossa K Inj.","slug":"invossa-k-inj","phase":"phase_3","mechanism":"Invossa K is a gene therapy that delivers TGF-β1 to stimulate cartilage regeneration and reduce joint degeneration in osteoarthritis.","indications":["Osteoarthritis of the knee (Phase 3)"],"catalyst":""},{"name":"KLS-2031","genericName":"KLS-2031","slug":"kls-2031","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOT2FmUy0wVHpuaDBTQi1EZ3Fjdlh5dmNDNUJWMnFfMUVpMW0zQzh4RmtwenVxaWUyV3JQMThEaWVpdzRtVzVCbFN3Ql91ZFRablVaWGg1cWVFZEZpOFl0ckRPcUxNUGdiMUw4eF9CVTFyUGxBelFDUi1nOFZRU0dNU0ZzbGQxV0x0MmdieHQ2VXpZVUk1N1hKSA?oc=5","date":"2026-04-05","type":"pipeline","source":"Seoul Economic Daily","summary":"Kolon Life Science, AriBio, Macrogen Lead Pharma-Bio CEO Shakeup - Seoul Economic Daily","headline":"Kolon Life Science, AriBio, Macrogen Lead Pharma-Bio CEO Shakeup","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RdIBV0FVX3lxTE1kamc3STMxanJzejl5X0I2d19zbzBpVEIyV1JIUG9Qemc3dzEtZTJudGlzX1hyYTRNc3ZPaGJkZk5leWdTLXlKSDRzSnFCNXRtTjVqVW13RQ?oc=5","date":"2026-04-02","type":"pipeline","source":"aju press","summary":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center - aju press","headline":"Korean Pharma-Bio Briefing: Kolon Life Science, Daewoong, Celltrion, Daewon, Samsung Medical Center","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE42MXA5UUM0R190NVFHZE13MWdpODh3RGpYVnYyZTN6N0wwc3pSV0NFU1duQ1pIbmdadjZSYzNJa3N1cm9iYWQ2ZXFvSFVSZ3lrSEc0S2RxcXJiMm9vVVIxOEFmZWYzcFBNMEh2c2tn0gFyQVVfeXFMT1Q2WUNwUW9YU3RTYWJRWUdfTXk1bWd5MTRwNjVBMWFEcTN0QXVpNlBQelhrTFpucmlBS01YTHNyQ0NiWlVCZktXbk1WWDZOYXdPMHAyYjRCNVZ3elZNZl9jWWF3VEtMbVJRQUc2a2h3Wl9n?oc=5","date":"2026-03-27","type":"pipeline","source":"koreabiomed.com","summary":"Kolon Life Science names Lee Han-guk as new CEO - koreabiomed.com","headline":"Kolon Life Science names Lee Han-guk as new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE1qelV1OEJzYTAyWVkwOFhOTnJlTGNlM3F6SGtpSjNhWl9sVXRLb1c3STVEREEtVHU3OVAtaTlwNXdHVDB1NDJiQ3RBRQ?oc=5","date":"2026-03-27","type":"pipeline","source":"매일경제","summary":"Kolon Life Sciences announced on the 27th that it held a general shareholders' meeting and board mee.. - 매일경제","headline":"Kolon Life Sciences announced on the 27th that it held a general shareholders' meeting and board mee.. - 매일경제","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQakZpME9uSl9zN3RGNlpBZnlJY1JCQThrTy1HZTljVXFRN2hkUk8wekZEeUhrYkhXclo0U3VvQk9XWkFmUDFFcUZHNEVfZks2ZDEwQlIzWGMtSUdMckpGdExvNlkzc1pjMzFtYVVSZUY0T1EzZWVqWUdVNG94T2lFZdIBlAFBVV95cUxNSkRCNlBRNjdqSlJkQTBJM2tGeHBPZFNSZ0hIWEZzODA5XzJ6dTRVS2N6MHNqOTJ0YkpuNGJmX2RldFVjaVN1cEpGOHRMQklxU0hqZzVpTmZXZ0x5cjA2NjZuQ3lzTWVIY09jakFuNmVWSVpoVTJkZElKdWdZX0VyUENJcGdSalQxZ2RfazlLX2diN044?oc=5","date":"2026-03-27","type":"pipeline","source":"Chosunbiz","summary":"Kolon Life Science names Lee Hanguk CEO to drive global biotech growth - CHOSUNBIZ - Chosunbiz","headline":"Kolon Life Science names Lee Hanguk CEO to drive global biotech growth - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOU3hMZTZ2b0lXTVZiVmxlVkZFaF9qM2cxaDNxbmZjQnJSVU9ramgwWVRuemUxc1RRUXhaZm0xa3MtSE84bE55cnpuWlhQd2VFMVNXOXlpNkdHMElvTmJ4bHhkWFBYb3NZV29qTjZKTkd4cmdMVWJVNUNHeWJtQVVRZdIBlAFBVV95cUxPZWtwVm9kN190WHpZaml0TnZlUnpkS1E3WDhWT1VzdUM1N1VCNVFlMTdjcjdzaGJXdXdTUm5DbEJrOGNhWUNlYVl6b3BFTEtiSlVmTUdRTWRZeEo5ekJwMW5YZUllak1oZFdfcTBQSzdQSk9zX3V4V0w5bUsza1RxWXlmLWNDTC0yVHEtY0lRWFp1M1Bw?oc=5","date":"2026-03-26","type":"pipeline","source":"Chosunbiz","summary":"Kolon Life Science taps Lee Hanguk to drive TG-C push and bio growth - CHOSUNBIZ - Chosunbiz","headline":"Kolon Life Science taps Lee Hanguk to drive TG-C push and bio growth - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1ULUlKTlhzMHlxU3pXaEhwbm03MFp0ZDNhdHhpWXgxZ2ViUERwWmIyVVMtNWFtVTdOb01SNjJ3Z2xQQ3l6QlJvRnVQdGxGUTZCWEhhZWV3eGtHNUJqUmgzMHkzbktGR2o0TGY5c1Jn0gFyQVVfeXFMTS1jMjlfTTNTbEh4cmh3X3ZsXy01cXNtb3libWNRMGc3bkk2N1EyOTZ6OW5xSzk5dUF3ZlRfSF9sQVM2NWVldVhfektrTUlRejB5SWdsLW5iWGZmRnBibUpKWE1rUjJOWm54czdYUDVEWEJR?oc=5","date":"2026-02-25","type":"pipeline","source":"koreabiomed.com","summary":"Kolon Life Science faces leadership vacuum as CEO Kim exits amid pivotal gene therapy push - koreabiomed.com","headline":"Kolon Life Science faces leadership vacuum as CEO Kim exits amid pivotal gene therapy push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5FSzhuaTZMYXozWDdPS3JOM056SmFsWmdka1d6QW9JVW9SSVp4TTAtSzVlSXFSMGhxbGJzOXFBZEdxQnNiNlV6ejhaeXd2NnR2Z2g3YlJnOXhyTE5YdUEtNkp5Y1I0NmVvcF9iOEdn0gFyQVVfeXFMTllWelZtNGt5ZUdxN29hTktkRXJzQm1icU5sb09BYTBRTk5XUEJhTnRLeExRbVl4VVJVNm1GWXVzcnQ0bnBmaENKbTM3WkxpS09xMFJSVWJERmJHcHN4YWNGWHlMeTF3bDJuV0NVdWJJWlNB?oc=5","date":"2025-04-23","type":"patent","source":"koreabiomed.com","summary":"Kolon Life Science secures Brazilian patent for neuropathic pain gene therapy candidate - koreabiomed.com","headline":"Kolon Life Science secures Brazilian patent for neuropathic pain gene therapy candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA0Y3JRYkZ5MzlNWlY0c1FxVnN4QV9GSF9SV2h4dEMzMGdaZEhVWVZrVUowUy1LWVN1c1VkWFdLTWNIUmJNQlRkdGJRUkNPS0pBWWxCVnJYOFoyRTRMNVRDaGFnSjZES2pMSUg5cGJ30gFyQVVfeXFMTTl0aUt1MVZ1OXBRSXBoNkNIV2p5elltbXBrdTNweHhYMTktYUZrOTdvd1B0Y1prbjdEbTlyVnBtRHp6YUNXNUpjanFCS3RYTm5oS2J5M2dMVnNfcnJCMGxDcUFmbzAyMzRGamdNYmdrZm1B?oc=5","date":"2024-02-29","type":"deal","source":"koreabiomed.com","summary":"Kolon Life Science appeals for Invossa's license reinstatement to Supreme Court - koreabiomed.com","headline":"Kolon Life Science appeals for Invossa's license reinstatement to Supreme Court","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5aVnFFckVGZXFRNldBZ1JTRWZKYUhNWFQxcWdlaGRUeEw1X1Q2WlZIbFpVc0dGTXE1VXFjVTZXUXV6VlVoWnZuTVR4VkdES2dsSkJtNHRSRjlkSlh5TTVTbWxucnJoY1BnY2o4Zmln?oc=5","date":"2022-04-13","type":"deal","source":"KED Global","summary":"Kolon Life inks technology transfer deal with Juniper Biologics - KED Global","headline":"Kolon Life inks technology transfer deal with Juniper Biologics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE5LOE5yZndOOWp6WDJqc2RKNTNHN1YyckF0WHlDS3RqaTI2U0V5dUY4bkswaHZudW5pNjhkZ0k5YVZUM2h5aW9NblB0Ujc3VmgtbWNNTFNuQWFPN3ZhWnBVYTNSclhvWm1KcXdlNVpuOUJoV0Q0?oc=5","date":"2021-12-28","type":"trial","source":"KED Global","summary":"Kolon resumes Invossa phase 3 clinical trials in US - KED Global","headline":"Kolon resumes Invossa phase 3 clinical trials in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNV19Ta0tfelhYRjlXTHdiQmZ3S0ZzbmUwRXp0cWl1c2FwaFhGNENlVlgxbEIwRWFIUi1wcllOQk5HWWlQNWhEbEdPVHJ3bTR6TnI0bkRFdGd6TWZkVlBFcFBMT05adkhFSE5NbVZtTEZXcm1yemlqOGxkYS1WVEFaZS05YjBRQkNPX2c?oc=5","date":"2018-11-19","type":"deal","source":"Pharmaceutical Technology","summary":"Mundipharma acquires rights for Invossa osteoarthritis therapy in Japan - Pharmaceutical Technology","headline":"Mundipharma acquires rights for Invossa osteoarthritis therapy in Japan","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}